search
Back to results

Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy

Primary Purpose

Appendicitis, Surgery

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Sugammadex
Neostigmine/Glycopyrrolate
Sponsored by
Emory University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Appendicitis focused on measuring laparoscopic

Eligibility Criteria

2 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients 2-17 years of age
  • Diagnosis of acute appendicitis
  • Patient undergoing laparoscopic appendectomy at Children's Healthcare of Atlanta- Egleston.
  • Parent or Legal Authorized Representative willing to participate, able to understand and sign an informed consent

Exclusion Criteria:

  • Patient with an allergy to Sugammadex or Neostigmine
  • History of renal dysfunction
  • Parent or legal guardian unwilling or unable or unable to understand the informed consent

Sites / Locations

  • Children's Healthcare of AltantaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Sugammadex

Neostigmine/Glycopyrrolate

Arm Description

The reversal agent, Sugammadex, will be administered at the start of closure.

The reversal agent, Neostigmine, will be administered at the start of closure.

Outcomes

Primary Outcome Measures

Total hours from surgery end to out of the operating room (OR)
Hours from surgery end to out of the OR will be evaluated via the Epic computer chart after discharge from the hospital.

Secondary Outcome Measures

Total hours to first bowel movement
Hours to first bowel movement will be evaluated via the Epic computer record after discharge from the hospital
Total hours to tolerance of an oral diet
The research team will evaluate via the Epic computer record after discharge from the hospital
Total hours of inhalational anesthesia exposure
will be evaluated via the Epic computer record after discharge from the hospital
Length of stay (hours) in the Post-anesthesia care unit (PACU)
PACU length of stay will be evaluated via the Epic computer record after discharge from the hospital
Hospital length of stay (LoS)
Hospital LoS will be evaluated via the Epic computer record after discharge from the hospital

Full Information

First Posted
February 16, 2022
Last Updated
September 12, 2023
Sponsor
Emory University
search

1. Study Identification

Unique Protocol Identification Number
NCT05256901
Brief Title
Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy
Official Title
Effectiveness of Sugammadex Versus Neostigmine on Neuromuscular Reversal in Pediatric Patients Undergoing Laparoscopic Appendectomy for Acute Appendicitis: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 19, 2023 (Actual)
Primary Completion Date
October 28, 2024 (Anticipated)
Study Completion Date
March 19, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed as a randomized controlled trial with patients assigned to neuromuscular reversal with either sugammadex or neostigmine/glycopyrrolate reversal. The study will not be blinded to the anesthesiologist to allow for appropriate decision-making on timing and dosage of reversal. This is a single-center study.
Detailed Description
Patients presenting to the operating room for laparoscopic appendectomy with a diagnosis of acute appendicitis require rapid sequence induction (RSI) due to significant vomiting and concern for increased gastric content. For this reason, succinylcholine-accompanied by neostigmine-is predominately used in adults for RSI to prevent potential aspiration. Unfortunately, in pediatric patients, there are many concerns about the use of succinylcholine, including complications such as bradycardia, hyperkalemia, dysrhythmias, and cardiac arrest from undiagnosed skeletal muscle myopathy. For many anesthesiologists, these concerns prompted the decision to use a non-depolarizing muscle relaxant such as rocuronium for induction. However, if the standard RSI dose is used, it often results in residual paralysis at the end of short procedures such as laparoscopic appendectomies. It has recently been demonstrated that prolonged paralysis is prevalent even at low doses of rocuronium in pediatric patients. For these reasons, it is imperative to find a way to provide adequate and safe RSI conditions for intubation, appropriate muscle relaxation for laparoscopic procedures, and the ability to quickly reverse neuromuscular blockade in this pediatric population. Sugammadex has the potential to allow for the utilization of an appropriate RSI dose of rocuronium for intubation, as it provides the ability to reverse neuromuscular blockade earlier than the neostigmine reversal, which is currently the standard of care. Retrospective reviews have shown the use of Sugammadex in pediatric patients to be safe and effective. However, there has not been prospective data about the effect on operating room efficiency on brief pediatric procedures such as laparoscopic appendectomies-one of the most common urgent pediatric surgeries performed. There are numerous other potential benefits of using sugammadex over typical reversal including the quicker return of bowel function, faster time to tolerance of an oral diet, and decreased exposure to volatile anesthesia. The return of bowel function is particularly important in pediatric patients undergoing laparoscopic procedures. The research team hypothesis is that the utilization of sugammadex in pediatrics results in a quicker return to bowel function. This has previously been demonstrated in adults, but data is lacking in the pediatric population. Researchers also hypothesize that patients receiving sugammadex versus neostigmine reversal will have an improved time to tolerance of an oral diet, which may impact wound healing and nutrition. As anesthesiologists often under-dose rocuronium in these short procedures, due to a lack of quick reversal options, high levels of volatile anesthesia are utilized to compensate for inadequate muscle relaxation. With the use of sugammadex allowing for proper muscle relaxation throughout the entire case, researchers hypothesize that patients will have a lower total volatile anesthetic exposure during the procedure. This is exceedingly important in pediatric anesthesia, where the detrimental effects of volatile anesthetics on the developing brain have been demonstrated in numerous animal studies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Appendicitis, Surgery
Keywords
laparoscopic

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sugammadex
Arm Type
Experimental
Arm Description
The reversal agent, Sugammadex, will be administered at the start of closure.
Arm Title
Neostigmine/Glycopyrrolate
Arm Type
Active Comparator
Arm Description
The reversal agent, Neostigmine, will be administered at the start of closure.
Intervention Type
Drug
Intervention Name(s)
Sugammadex
Other Intervention Name(s)
Intervention Group
Intervention Description
Participants will receive 4mg/kg for a TOF 0-1 and 2mg/kg for a train of four (TOF) 2 or greater.
Intervention Type
Drug
Intervention Name(s)
Neostigmine/Glycopyrrolate
Other Intervention Name(s)
Regular Care
Intervention Description
Participants will receive 0.07mg/kg of Neostigmine and 0.01mg/kg of Glycopyrrolate, administered by anesthesia once at least two twitches are present.
Primary Outcome Measure Information:
Title
Total hours from surgery end to out of the operating room (OR)
Description
Hours from surgery end to out of the OR will be evaluated via the Epic computer chart after discharge from the hospital.
Time Frame
Up to 2 hours
Secondary Outcome Measure Information:
Title
Total hours to first bowel movement
Description
Hours to first bowel movement will be evaluated via the Epic computer record after discharge from the hospital
Time Frame
Up to 72 hours
Title
Total hours to tolerance of an oral diet
Description
The research team will evaluate via the Epic computer record after discharge from the hospital
Time Frame
Up to 72 hours
Title
Total hours of inhalational anesthesia exposure
Description
will be evaluated via the Epic computer record after discharge from the hospital
Time Frame
Up to 5 hours (depending on length of surgical procedure)
Title
Length of stay (hours) in the Post-anesthesia care unit (PACU)
Description
PACU length of stay will be evaluated via the Epic computer record after discharge from the hospital
Time Frame
Up to 5 hours (depending on post anesthesia recovery)
Title
Hospital length of stay (LoS)
Description
Hospital LoS will be evaluated via the Epic computer record after discharge from the hospital
Time Frame
Up to 14 days (depending on length of hospitalization)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients 2-17 years of age Diagnosis of acute appendicitis Patient undergoing laparoscopic appendectomy at Children's Healthcare of Atlanta- Egleston. Parent or Legal Authorized Representative willing to participate, able to understand and sign an informed consent Exclusion Criteria: Patient with an allergy to Sugammadex or Neostigmine History of renal dysfunction Parent or legal guardian unwilling or unable or unable to understand the informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Gilbertson, MD
Phone
404-785-6670
Email
lgilbe5@emory.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laura Gilbertson, MD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Healthcare of Altanta
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The research team will share Individual participant data that underlie the results (text, tables, figures, and appendices) reported in the article, after the deidentification
IPD Sharing Time Frame
The research team will share the data immediately following publication and ending 3 years following article publication.
IPD Sharing Access Criteria
Proposals should be directed to laura.gilbertson@emory.edu. To gain access, data requestors will need to sign a data access agreement.

Learn more about this trial

Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy

We'll reach out to this number within 24 hrs